Physician profile
Annie Hyon
NPI 1508007451
$2,216.97
in general payments reported to CMS, 2019-2025
22 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $386 · 2021: $351 · 2022: $156 · 2023: $384 · 2024: $118 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $25.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.75 |
| Education | $25.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $469.58 | 2019-2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $261.00 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $143.16 | 2019-2022 | |
| Medtronic, INC. | $140.19 | 2025 | Symplicity G3 |
| Bayer Healthcare Pharmaceuticals INC. | $138.75 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $126.99 | 2019-2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $123.90 | 2021 | |
| Vifor Pharma, INC. | $101.00 | 2019-2021 | |
| Travere Therapeutics, INC. | $97.30 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $86.57 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $82.05 | 2021 | |
| Amgen INC. | $75.80 | 2019-2025 | Tavneos |
| Ardelyx, INC. | $71.60 | 2024-2025 | Ibsrela |
| Baxter Healthcare | $62.17 | 2020 | |
| Akebia Therapeutics INC | $47.93 | 2019-2025 | Vafseo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $45.53 | 2019 | |
| Amag Pharmaceuticals, INC. | $34.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.88 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $25.28 | 2020 | |
| Genzyme Corporation | $19.76 | 2019 | |
| Amicus Therapeutics, INC. | $17.03 | 2019 | |
| Daiichi Sankyo INC. | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Hyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.